Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer. (PubMed, Clin Pharmacol Ther) - Sep 11, 2026 - "Responses attained with higher early cycle exposure were not impacted by subsequent dose modifications. Overall, exposure-response analysis supports the use of enfortumab vedotin at a starting dose of 1.25 mg/kg and in combination with pembrolizumab for first-line treatment of locally advanced or metastatic urothelial cancer."
Journal • Diabetes • Genito-urinary Cancer • Oncology • Pain • Solid Tumor • Urothelial Cancer
|
|
Amit Garg; Daping Zhang; Helen Kastrissios; Hossam Kadry; Russ Wada; Salaheldin Hamed; Souvik Bhattacharya; Srinivasu Poondru; Vaishali L Chudasama; Yen Lin Chia
|